Skip to content

Author

Diana Barb

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Oct 2026

Using Homeostatic Model Assessment of Insulin Resistance to Improve Metabolic Dysfunction-Associated Steatotic Liver Disease Risk Stratification in Individuals with Type 2 Diabetes from Primary Care and Endocrinology Settings.

OBJECTIVES Current metabolic dysfunction-associated steatotic liver disease (MASLD) guidelines recommend fibrosis screening in individuals with type 2 diabetes (T2D) because of their increased risk of clinically significant fibrosis (≥F2). However, fibrosis risk is variable, and clinical tools to identify individuals a...

N. Cuervo-Pardo, S. Kalavalapalli, Eddison Godinez Leiva et al. · 0 citations
Oct 2026

Prediabetes and diabetes as drivers of fibrosis in MASLD: roles of obesity, adipose tissue dysfunction and insulin resistance.

In a real-world cohort from primary care/endocrinology clinics, the prevalence of MASLD increased in a stepwise manner with glycaemic and BMI categories, but the prevalence of fibrosis did not increase in the same stepwise manner and remained rare in the absence of obesity, or in obesity without significant insulin res...

Eddison Godinez Leiva, Diana Barb, S. Kalavalapalli et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.